Pure Global
NCT02988843

Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors

Phase II Study of Brentuximab Vedotin and Bevacizumab in Men With Refractory CD-30 Positive Germ Cell Tumors
Masonic Cancer Center, University of Minnesota·Phase 2·ClinicalTrials.gov·drugTerminated
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Germ Cell Tumor
Drug/Device/Intervention
Brentuximab Vedotin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Masonic Cancer Center, University of Minnesota
Location
Minneapolis, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Mar 29, 2017
End date
Dec 15, 2019
Enrollment
1 participants
Primary outcome

Disease Response Rate as Defined by the RECIST 1.1 Criteria, Integrated With Tumor Marker Response.

Summary

This is a multi-center phase II study of brentuximab vedotin in combination with bevacizumab
 for the treatment of refractory CD-30+ germ cell tumors (GCT) after disease progression on
 imaging and/or tumor marker progression documented by serially rising alpha-fetoprotein (AFP)
 or beta human chorionic gonadotropin (bHCG) measured on at least 2 consecutive visits and
 determined by treating physician to be clinically significant. Patients unable to receive 2nd
 line of platinum-based chemotherapy due to toxicity or refusal would also be eligible.

ICD-10 classifications
Malignant neoplasmsMalignant neoplasm: JejunumMalignant neoplasm: PrepuceMalignant neoplasm: Female genital organ, unspecifiedMalignant neoplasm: Vulva, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT02988843
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT02988843 through Pure Global AI's free database. This Phase 2 trial is sponsored by Masonic Cancer Center, University of Minnesota and is currently Terminated. The study focuses on Germ Cell Tumor. Target enrollment is 1 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.